Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s research lab, which is located in Boston… The company also received FDA approval for its IND application to proceed with a feasibility study using Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In addition, Cybin launched a first-of-its-kind psychedelic facilitator training program based on EMBARK, a groundbreaking psychotherapy model,” reads a recent article. “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline and overall business,” said Cybin CEO Doug Drysdale.
To view the full article, visit https://ibn.fm/3WXKM
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.